MAPT and Alzheimer disease: This is the case of immunization of triple transgenic AD-like mice with a full-length DNA of amyloid β1–42 peptide, which showed a 40% reduction in the brain content of the amyloid β1–42 concomitant with a 25–50% decrease of total tau and different phosphorylated tau isoforms [314].